Skip to content
Peptide research

Imunofan

Also known as Immunomodulatory Hexapeptide
Category
Bioregulators
Administration routes
InjectableNasal
Regulatory status
Not FDA-approved

A synthetic hexapeptide marketed as an immune modulator for infection recovery and immune balance. Only immune normalization has moderate support; tissue repair, vaccine adjuvant use, epigenetic effects, and anti-tumor support are speculative, mechanism-only, and barely studied in humans. Safety evidence remains limited. Russian labeling lists individual intolerance and possible temporary exacerbation of chronic inflammatory foci. Not FDA-approved, and products sold online are unregulated.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Imunofan (also spelled Immunofan) is a synthetic hexapeptide with the amino acid sequence RDKVYR (Arg-Asp-Lys-Val-Tyr-Arg), marketed as an immunomodulatory agent. Like Cortexin, it is a registered pharmaceutical drug in Russia rather than just a dietary supplement. Imunofan was developed as a synthetic modification of the thymic hormone thymopoietin and is used clinically in Russia for immunodeficiency states, vaccine adjuvant activity, oncological support, and infectious disease management.

A 2020 study published in Molecules (MDPI, open access) investigated Imunofan's ability to stimulate skin cell proliferation and promote tissue repair. The study found that Imunofan displayed stability in aqueous solutions, exerted significant pro-proliferative activity (30-40% increase in fibroblast proliferation, 20-50% increase in keratinocyte proliferation), showed no cytotoxicity over a vast concentration range, and had no allergic properties. It also induced significant transcriptional responses including enhanced DNA demethylation gene activity. A 2025 study (PMID 41116267) evaluated solid-phase synthesized Imunofan as a vaccine adjuvant, finding clinically relevant adjuvant activity compared to Freund's adjuvant.

Imunofan is available as nasal spray, suppositories, and injectable solution in Russia. It has a well-defined molecular structure (unlike the polypeptide complex bioregulators), which has enabled more rigorous pharmacological characterization.

How it works in the body

A synthetic hexapeptide (arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine) that modulates immune function at multiple levels. It restores the balance between Th1 and Th2 immune responses, stimulates antioxidant defense by increasing glutathione and ceruloplasmin levels, and enhances phagocytic activity without causing immune overstimulation.

Research overview

Imunofan has the most robust pharmacological characterization of any Khavinson-associated peptide, owing to its defined single-sequence structure (RDKVYR). The 2020 MDPI Molecules study provides detailed data on stability, cytotoxicity, pro-proliferative activity, and transcriptional effects. Key findings include: 30-40% increase in fibroblast proliferation, 20-50% increase in keratinocyte proliferation, enhanced DNA demethylation gene activity, activation of immune response/migration/chemotaxis genes in stem cells, and moderate tissue repair promotion in mouse ear pinna injury models (8-36% improvement). The 2025 adjuvant study (PMID 41116267) reports protection in vaccinated mice; human vaccine efficacy was not tested. Russian clinical literature describes extensive use in immunodeficiency, oncology (supportive care), and infectious diseases. The drug has been used clinically in Russia for over 25 years.

Who researches Imunofan?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching immune system support

    Studied for immune modulation, antiviral, or antimicrobial properties.

  • People researching experimental oncology peptides

    Studied for effects on cancer cell targeting or tumor biology in preclinical research.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

Do not use if

  • Children under 2 under Russian nasal-spray labeling

    Absolute

    The Russian label permits use in older children; this does not establish FDA approval or comprehensive pediatric safety.

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Allergic reaction

    Low

    PMID 32585846; PMID 10377887

  • Potential immune modulation in autoimmune conditions

    Theoretical

    PMID 10377887; PMID 11764501

  • Injection site reactions (injectable form)

    Low

    PMID 10377887; PMID 32585846

Interaction summary(8)

Rated by direction with this peptide

  • MRP/MDR-substrate chemotherapy (e.g. vincristine, anthracyclines, etoposide)

    CautionModerate

    The published pharmacology is explicitly bidirectional: Imunofan inhibited multidrug-resistance transport proteins during substrate transport but INCREASED their activity in the latent period, with >1000-fold greater inhibitory potency than other substrate analogues and a protein-kinase-C-dependent mechanism (PMID 17603672); the 2004 tumor-cell report is indexed title-only (PMID 15255157). Altered efflux could raise intracellular cytotoxic drug levels and toxicity, or conversely prime resistance - either outcome is clinically consequential. All data are preclinical; no human co-administration or drug-level study exists, and a net benefit has never been shown.

    PMID 15255157; PMID 17603672

  • Radiotherapy and cytotoxic chemotherapy regimens (supportive use)

    ProtectiveLow

    In an endometrial adenocarcinoma series, adding Imunofan to radiation/chemoradiation was associated with fewer radiation-induced complications and restoration of lymphocyte subsets and neutrophil phagocytic activity (PMID 11764501), consistent with the review's claim of enhanced free-radical/oxidant inactivation and shortened radiation and toxic reactions (PMID 10377887). Evidence quality is low: a single small non-randomized, unblinded series with no independent replication, so 'protective' describes the reported direction, not a demonstrated effect.

    PMID 11764501; PMID 10377887

  • Cyclosporine and other calcineurin-inhibitor immunosuppressants

    CautionTheoretical

    Pharmacodynamic opposition only: an agent marketed to restore cell-mediated immunity and raise CD3+/CD4+/CD8+ counts runs against deliberate immunosuppression, which would matter in transplant recipients or patients on maintenance immunosuppression. No clinical, pharmacokinetic or drug-level data exist in either direction.

    PMID 10377887; PMID 11764501

  • Systemic corticosteroids

    CautionTheoretical

    Mechanism-based only: corticosteroids suppress the cell-mediated responses, cytokine signaling and neutrophil oxidative burst that Imunofan is reported to restore, so concurrent use would be expected to blunt its pharmacodynamic effect. No interaction study of any kind exists; this is inference from the mechanism review, not an observed interaction.

    PMID 10377887

  • Fluoroquinolone antibiotics (moxifloxacin) in C. difficile infection

    CautionTheoretical

    In vitro only, and concentration-dependent in both directions. Imunofan alone at 0.05-0.25 ug/ml showed antimicrobial activity against a toxigenic C. difficile strain, and maximum combined growth inhibition occurred at 1.5 ug/ml imunofan with 2.5x MIC moxifloxacin. Correction: the growth-stimulating range is moxifloxacin 0-1.5x MIC (not merely sub-MIC), and stimulation occurred regardless of imunofan concentration. The pairing therefore cannot be assumed beneficial at clinical exposures; no in vivo or human data.

    PMID 32762196

  • Vaccines (as co-administered adjuvant)

    SynergisticTheoretical

    In BALB/c mice (n=10/group), Imunofan co-administered with a chimeric E. coli O157:H7 antigen produced shedding reduction comparable to Freund's adjuvant despite markedly lower IgG titers. A single unreplicated mouse study published online-ahead-of-print in a low-tier journal; the lower antibody response means it could equally under-perform for antibody-dependent vaccines. No human vaccine co-administration data, and the effect on approved vaccine schedules is unknown.

    PMID 41116267

  • Biologic immunosuppressants / anti-TNF and other cytokine-blocking therapy

    CautionTheoretical

    Imunofan is reported to lower TNF and IL-6 while restoring cell-mediated immunity - an overlapping-but-opposing profile to cytokine blockade. Combining an immune-restorative peptide with biologic therapy for autoimmune disease has never been studied and could destabilize disease control. Pure mechanistic inference from a narrative review; no case reports or studies exist.

    PMID 10377887

  • Antiretroviral and other chronic antiviral regimens (hepatitis B/C, opportunistic infection)

    NeutralTheoretical

    The review describes Imunofan being used within combination therapy for chronic hepatitis B/C, brucellosis and opportunistic infections, reporting enhanced antiviral/antibacterial immunity - it does NOT report antiretroviral co-administration, drug levels or absence of pharmacokinetic interference. No formal interaction or drug-level study has been published for any antiviral, so a neutral interaction is assumed from uneventful concomitant use, not demonstrated.

    PMID 10377887

Known risks(3)

  • Allergic reaction

    Low

    The 2020 study found no allergic response in its laboratory tests; it did not establish a clinical allergy rate.

  • Potential immune modulation in autoimmune conditions

    Moderate

    As an immunomodulator, Imunofan could theoretically affect autoimmune conditions. However, it is described as 'normalizing' rather than purely stimulatory.

  • Injection site reactions (injectable form)

    Low

    Minor injection site reactions possible with IM/SC administration.

Drug interactions(3)

  • Immunosuppressants

    Potential antagonism with immunosuppressive therapy; clinical monitoring required

  • Vaccines

    Adjuvant activity demonstrated; may enhance vaccine immune response

  • Chemotherapy agents

    Used as supportive therapy during chemotherapy in Russian oncology practice

Research & benefits

Evidence base

Evidence Level
Moderate Evidence (registered drug with published studies in international journals)
Total Studies
30
Human Participants
5000

Imunofan has the strongest evidence profile among Khavinson-associated peptides. It has a defined molecular structure enabling rigorous study, a 2020 MDPI publication with detailed in vitro and in vivo data, a 2025 adjuvant study, and decades of Russian clinical use as a registered pharmaceutical. The MDPI study provides Western-accessible peer-reviewed data on mechanism and efficacy. Russian clinical trials have enrolled thousands of patients across multiple indications.

Researched for(5)

Rated by confidence in the evidence

  • Immunomodulatory activity (immune system normalization)

    Medium

    Multiple human studies, including one randomized trial, show immune parameter improvements.

    PMID 10377887; PMID 11764501; PMID 20481041; PMID 20020612; PMID 8771665

  • Skin cell proliferation and tissue repair promotion

    Speculative

    Single 2020 study: boosted skin cell growth and wound closure in mice, no human data.

    PMID 32585846

  • Vaccine adjuvant activity

    Speculative

    Single 2025 mouse study suggests adjuvant effect against one bacterial antigen, unreplicated.

    PMID 41116267

  • DNA demethylation gene activation (epigenetic effects)

    Speculative

    Fibroblast study suggested altered DNA-demethylation gene activity, though results were inconsistent across genes.

    PMID 32585846

  • Anti-tumor support (immune-mediated)

    Speculative

    Limited to a small supportive-care study and unconfirmed preclinical mechanism data, not tumor outcomes.

    PMID 11764501; PMID 15255157; PMID 17603672

Benefits(5)

  • Immunomodulatory activity (immune system normalization)

    Russian pharmaceutical registration data; decades of clinical use

  • Skin cell proliferation and tissue repair promotion

    Molecules 2020 (MDPI); fibroblast 30-40% increase, keratinocyte 20-50% increase

  • Vaccine adjuvant activity

    PMID 41116267 (2025); solid-phase synthesized Imunofan vs. Freund's adjuvant

  • DNA demethylation gene activation (epigenetic effects)

    Molecules 2020 (MDPI); transcriptional response analysis

  • Anti-tumor support (immune-mediated)

    Russian oncology clinical data; Bespalov et al. tumor incidence reduction study

Key studies(2)

  1. Imunofan -- RDKVYR Peptide -- Stimulates Skin Cell Proliferation and Promotes Tissue Repair

    In vitro + in vivoCell lines + mouse modelsVariable (cell culture + wound healing timeline)

    Sawicka J, Dzierzynska MA, Wardowska A, Deptula M, et al.

    Molecules (MDPI)

    2020

    Imunofan showed 30-40% fibroblast and 20-50% keratinocyte proliferation increase, no cytotoxicity, no allergic properties, enhanced DNA demethylation genes, and moderate tissue repair (8-36%) in mouse ear pinna injury model.

  2. Authors not fully retrieved

    PubMed-indexed journal

    2025

    Solid-phase synthesized Imunofan demonstrated clinically relevant adjuvant activity comparable to Freund's adjuvant, supporting its use as a vaccine enhancer.

Regulation & availability

Why researchers look at it

Imunofan is the most pharmacologically characterized Khavinson-associated peptide, with a defined hexapeptide sequence, MDPI-published efficacy data, and decades of Russian clinical use. It bridges traditional bioregulator research with modern peptide pharmacology.

Estimated cost
$30-80/course (nasal spray or injection; available in Russia)
FDA status
Not FDA-approved; registered pharmaceutical in Russia; defined synthetic peptide structure
WADA status
Not listed on WADA Prohibited List; not evaluated by WADA
Prescribability
Registered drug in Russia; available by prescription in CIS countries; not approved in USA/EU
Availability
Available as nasal spray, rectal suppositories, and injectable solution in Russia. The defined synthetic structure means it can be produced by peptide synthesis. Not available through conventional channels in the USA or EU.

International status

  • EU

    Not approved

  • US

    Not approved; not available

  • CIS

    Approved in multiple CIS countries

  • Russia

    Registered pharmaceutical (approved for immunodeficiency, adjunct oncology)

  • Worldwide

    Approved primarily in Russia

Regulatory timeline(4)

  1. 1990s
    Developed and registered as pharmaceutical in Russia
  2. 2000s
    Widely prescribed in Russian immunology and oncology practice
  3. 2020
    MDPI Molecules study on skin proliferation and tissue repair published
  4. 2025
    Adjuvant activity study published (PMID 41116267)

Sources & FAQs

Research sources(4)

Frequently asked questions(4)

What is Imunofan's chemical structure?

Imunofan is a synthetic hexapeptide with the sequence RDKVYR (Arg-Asp-Lys-Val-Tyr-Arg). It is a defined single-sequence molecule, unlike the complex polypeptide mixtures in most Khavinson bioregulators. This makes it more amenable to rigorous pharmacological study.

How is Imunofan administered?

In Russia, Imunofan is available as a nasal spray (for daily immunomodulation), rectal suppositories, and injectable solution (subcutaneous or intramuscular). The nasal spray form is most convenient for chronic use.

What conditions is Imunofan used for in Russia?

Imunofan is prescribed for immunodeficiency states, as adjuvant therapy in oncology (to support immune function during chemotherapy), in chronic infectious diseases, for vaccine enhancement, and in allergic conditions. It is also studied for wound healing and tissue repair applications.

Is Imunofan the same as thymopoietin?

No. Imunofan is a synthetic modification derived from a fragment of thymopoietin (a natural thymic hormone). It retains immunomodulatory activity but has been optimized for stability and clinical use.